https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14380 Wed 11 Apr 2018 13:23:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25029 Wed 06 Apr 2022 14:00:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29675 Wed 02 Mar 2022 14:26:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54512 Tue 27 Feb 2024 15:39:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34050 Thu 28 Oct 2021 13:03:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32180 .37 for interaction). Similarly, the treatment effects of low- vs standard-dose alteplase on function outcome (ordinal shift of the modified Rankin Scale) in Asians (odds ratio, 1.05; 95% CI, 0.90-1.22) was consistent with non-Asians (odds ratio, 0.93; 95% CI, 0.76-1.14) (P = .32 for interaction). There were generally consistent reductions in rates of symptomatic intracerebral hemorrhage with low-dose alteplase, although this reduction was not statistically significant by age, ethnicity, or severity. Conclusions and Relevance: This analysis found that the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability in key demographic subgroups of patients with AIS. Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase. Trial Resgistration: clinicaltrials.gov Identifier: NCT01422616.]]> Thu 27 Jan 2022 15:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53942 Mon 22 Jan 2024 16:58:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41708 Fri 12 Aug 2022 08:09:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38488 Fri 08 Oct 2021 16:17:10 AEDT ]]>